摘要
目的探讨新诊断T2DM患者血清miR-126表达水平与非酒精性脂肪性肝病(NAFLD)的相关性。方法选取2016年7月至2017年7月于我院内分泌科就诊的188例新诊断T2DM患者,根据肝脏彩色超声结果分为T2DM组(n=92)及T2DM合并NAFLD组(NAFLD,n=96),按照血清miR-126表达水平三分位数将新诊断T2DM患者分成3组,行肝脏彩色超声检查、相关生化指标和血清miR-126表达量的测定。结果NAFLD组血清miR-126表达量低于T2DM组[(0.43±0.19)vs (0.78±0.31),P<0.01];Person相关分析提示,血清miR-126表达量与胰岛素抵抗指数(HOMA-IR)(r=-0.664,P<0.01)和高敏C反应蛋白(hsC-RP)(r=-0.273,P=0.023)呈负相关。Logistic回归分析结果显示,校正BMI、WC、血脂、hsC-RP后,血清miR-126表达量是NAFLD的保护因素(OR=0.158,95%CI0.032～0.838,P=0.036)。但校正HOMA-IR后,血清miR-126表达量与NAFLD无相关性(P>0.05)。随着血清miR-126表达水平的升高,NAFLD患病率逐渐下降(86.95%vs 52.17%vs17.39%,P<0.01)。结论新诊断T2DM患者血清miR-126表达水平与NAFLD密切相关,IR可能参与了这一过程。
Objective To explore the association between serum miR-126 and non-alcoholic fatty liver disease in patients with newly diagnosed type 2 diabetes（T2DM）. Methods A total of 188 subjects with newly diagnosed T2DM were enrolled in this study and divided into two groups according to their hepatic ultrasonography results：Patients without NAFLD （T2DM group,n=92）and patients with NAFLD group（NAFLD,n=96）.Their clinical,lipids,liver function,insulin,hsC-RP and serum miR-126 expression level were measured. Results Serum miR-126 expression level was lower in NAFLD group than in Non-NAFLD group [（0.43±0.19）vs（0.78±0.31）,P〈0.01].Pearson analysis showed that serum miR-126 expression level was negatively correlated with HOMA-IR （r=-0.664,P〈0.01）and hsC-RP（r=-0.273,P=0.023）.According to logistic regression analysis,after adjustment for BMI,waist circumference（WC）,lipid,hsC-RP,serum miR-126 expression level（OR=0.158,95% CI0.032～0.838,P=0.036）was correlated with NAFLD.However,after adjustment of HOMA-IR,this correlation disappeared （P〈0.05）.All subjects were then divided into three groups according to the tertiles of serum miR-126 expression level,the prevalence of NAFLD decreased together with the elevation of serum miR-126 expression level（86.95% vs 52.17% vs 17.39%）. Conclusion Serum miR-126 expression level is significantly correlated with NAFLD in patients with newly diagnosed T2DM.Insulin resistance（IR）may participate in this process.
作者
宋白利
付留俊
刘婕
常毅娜
张文博
袁圆
姜宏卫
SONG Baili;FU Liujun;LIU J ie(Department of Endocrinology,First Affiliated Hospital of Henan University Technology,Luoyang 4 71003,China)
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2018年第10期812-816,共5页
Chinese Journal of Diabetes
基金
河南省医学科技攻关计划项目(201602168)
